The 5th annual LSX World Congress is the new name for the Biotech and Money / Medtech and Money World Congress. The name may have changed, but it retains its core offering for the C-suite of the global life science industry.

The LSX World Congress is a high-calibre, senior executive, two-day conference and partnering event providing the education, strategies, solutions and contacts that life science executives need to enable more effective investment, planning and strategic growth within their businesses.

Leena Ylösmäki, Director of Pre-clinical Development, has over 15 years of experience in the fields of basic and applied virology and cancer research. During her academic career, she has studied various different viruses including Influenza A, vaccinia and adenoviruses. Before joining Valo Therapeutics, Leena worked as a PhD researcher at the university of Helsinki where she designed and developed various oncolytic viruses for cancer immunotherapy.

Petra Ahokas, Laboratory Manager, has over 10 years of experience working in laboratories, both as a research assistant and as a scientist, mostly in the field of cancer research. She joined Valo Therapeutics in 2018 and was tasked with opening and managing Valo's new research and development laboratory. Before joining Valo Therapeutics, Petra worked in cancer research at the University of Helsinki and extensively with oncolytic viruses as a Research Scientist at Oncos Therapeutics (now Targovax).

The NeoAg Summit (formerly Neoantigen Summit) is the 3rd annual industry focused meeting dedicated to advancing neoantigen based cancer vaccines and cell therapies. Our aim is to bring together the pioneers supercharging next generation immunotherapies to accelerate safe, effective and scalable neoantigen-based therapies.

The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) are proud to once again join forces to present the International Cancer Immunotherapy Conference. The program will focus on “Translating Science into Survival” and feature talks from more than 60 leaders in the field covering all areas of inquiry in cancer immunology and immunotherapy.

SITC 2018 is the leading destination for scientific exchange, education and networking in the cancer immunotherapy field.

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. 

Oncolytic virotherapy represents an exciting new area of cancer treatment which exploits a virus’s ability to selectively replicate and kill tumor tissue while stimulating a patient-specific immune response against cancer. Interest in the field is at an all-time high following several significant deals. However, questions still remain around delivery, product and clinical development, pre-clinical modelling, scale-up, manufacturing and suitable commercial models.